drugset / Trial / NCT02467348

Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

NCT02467348

RandomizedParallel-groupOpen-labelTreatment

Summary

All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016.ACLF (Acute on chronic Liver Failure). ACLF will be randomize into Group 1: MVP (Modest Volume Paracentesis) OF Less than 5 liters with IV albumin at a dose 8 gms/L of ascitic fluid Group 2: MVP (Modest Volume Paracentesis) of Less than 5 liters without albumin

Timeline

Start
2015-03-15
Primary completion
2017-01-31
Completion
2017-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 8 g Intravenous

Indications